info@RegenProtocols.com
561-325-7000
141 NW 20th St., Suite G1 Boca Raton, FL 33431
A structured framework that supports post-surgical recovery and wound healing across the inflammatory, proliferative, and remodeling phases.
A structured clinical framework to optimize post-surgical recovery and improve wound healing across all biological phases: inflammation, proliferation, and remodeling. The protocol combines angiogenic peptides, collagen-stimulating compounds, immune modulators, and growth hormone secretagogues to speed tissue regeneration, improve vascularization, and lower the risk of delayed or chronic wound healing.
| Agent | Route | Dose | Frequency | Duration |
|---|---|---|---|---|
| BPC-157 | Subcutaneous (SubQ), perilesional | 250–500 mcg | Twice daily | 6–8 weeks |
| TB-500 (thymosin β4) | SubQ | 1.0–2.0 mg | Twice weekly (loading), then weekly (maintenance) | 8–12 weeks |
| GHK-Cu | SubQ or topical | 1–3 mg (SubQ) or topical formulation | Daily | 8–12 weeks |
| Agent | Route | Dose | Frequency | Duration |
|---|---|---|---|---|
| Thymosin α1 (Tα1) | SubQ | 1.6 mg | Twice weekly | 6–8 weeks |
| CJC-1295 / Ipamorelin | SubQ | 100 mcg / 100 mcg | Once daily (evening) | 8–12 weeks |
| KPV | SubQ or topical | 200–500 mcg | Daily | 4–6 weeks |
This protocol targets all three phases of wound healing at once. BPC-157 supports angiogenesis and VEGF expression to establish a blood supply to the wound bed. TB-500 enhances actin-mediated cell migration into the repair matrix. GHK-Cu stimulates collagen synthesis and glycosaminoglycan production and attracts reparative stem cells.
Thymosin α1 modulates immune surveillance to lower infection risk without excessive inflammation. CJC-1295/ipamorelin raise systemic growth hormone and IGF-1, which improves tissue remodeling during sleep-driven recovery cycles.
